Trading Report: Today, Eli Lilly and Co. (LLY) Given a $73.00 Price Target at Morgan Stanley

Today, Eli Lilly and Co. (LLY) Given a $73.00 Price Target at Morgan Stanley

Eli Lilly and Co. (NYSE:LLY) has been given a $73.00 price target by investment analysts at Morgan Stanley in a research report issued to clients and investors on Thursday. The brokerage presently has a “hold” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 5.61% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Argus raised their price target on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a report on Friday, July 29th. BMO Capital Markets reissued a “buy” rating and issued a $94.00 price target on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price target for the stock from $89.00 to $95.00 in a report on Tuesday, September 27th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $92.34.

Eli Lilly and (NYSE:LLY) traded up 1.65% during midday trading on Thursday, hitting $69.12. 8,620,682 shares of the stock traded hands. The stock has a market capitalization of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16. The stock’s 50-day moving average price is $76.69 and its 200-day moving average price is $77.92.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the business earned $0.89 EPS. Equities research analysts expect that Eli Lilly and will post $3.55 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be paid a $0.51 dividend. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio is presently 88.70%.

In related news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Ronna Sue Cohen raised its stake in shares of Eli Lilly and by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock valued at $218,000 after buying an additional 9 shares during the period. Tarbox Group Inc. raised its stake in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the period. Argent Trust Co raised its stake in shares of Eli Lilly and by 0.3% in the second quarter. Argent Trust Co now owns 4,184 shares of the company’s stock valued at $329,000 after buying an additional 12 shares during the period. First Citizens Bank & Trust Co. raised its stake in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock valued at $476,000 after buying an additional 18 shares during the period. Finally, Strategic Financial Group LLC raised its stake in shares of Eli Lilly and by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock valued at $277,000 after buying an additional 18 shares during the period. Institutional investors own 75.11% of the company’s stock.

Eli Lilly and Company Profile

Related posts

Leave a Comment